Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors

Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors

Bleeding complications limits the use of effective antithrombotics therapeutics. Here, the authors developed next-generation direct thrombin inhibitors with low bleeding risks as safe peri-percutaneous coronary intervention anticoagulants when used in combination with antiplatelets.

Guardado en:
Detalles Bibliográficos
Autores principales: Cho Yeow Koh, Norrapat Shih, Christina Y. C. Yip, Aaron Wei Liang Li, Weiming Chen, Fathiah S. Amran, Esther Jia En Leong, Janaki Krishnamoorthy Iyer, Grace Croft, Muhammad Ibrahim Bin Mazlan, Yen-Lin Chee, Eng-Soo Yap, Dougald M. Monroe, Maureane Hoffman, Richard C. Becker, Dominique P. V. de Kleijn, Vaishali Verma, Amita Gupta, Vijay K. Chaudhary, A. Mark Richards, R. Manjunatha Kini, Mark Y. Chan
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/cad6e99b695d4c66a9002c62027f15b1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Bleeding complications limits the use of effective antithrombotics therapeutics. Here, the authors developed next-generation direct thrombin inhibitors with low bleeding risks as safe peri-percutaneous coronary intervention anticoagulants when used in combination with antiplatelets.

Ejemplares similares